Abstract
Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological malignancies. Phase I clinical trials had been completed in several solid tumor types and phase II clinical trials had been completed in patients with small-cell lung cancer and NSCLC. A phase II clinical trial in patients with platinum-resistant ovarian cancer and phase I/II and phase II clinical trials in patients with acute leukemias were ongoing at the time of publication.
| Original language | English |
|---|---|
| Pages (from-to) | 647-657 |
| Number of pages | 11 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 9 |
| Issue number | 6 |
| State | Published - Jun 2008 |
Fingerprint
Dive into the research topics of 'SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver